Pharmacogenetics of ADRs: Warfarin Toxicity

ADR 的药物遗传学:华法林毒性

基本信息

  • 批准号:
    6875574
  • 负责人:
  • 金额:
    $ 34.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2008-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Iong-term aim of this research is to determine the clinical consequences of genetic variability within the human CYP2C9 gene among subjects of diverse ethnic origins, and to understand molecular mechanisms that underlie genetically-based alterations in the functional activity of the CYP2C9 enzyme. CYP2C9 is a major human liver form of P450 that metabolizes approximately 15% of all drugs that are cleared by phase I processes. It is well established that treating patients that possess the common CYP2C9*2 and CYP2C9*3 variants with low therapeutic index drugs, e.g. warfarin, has clinically important implications. These are adverse drug reactions (ADRs) due to over-medication that can result in significant, but potentially avoidable, patient health costs. Although a large body of information exists for certain CYP2C9 polymorphisms in Caucasian subjects, the full spectrum of genetic variation at the CYP2C9 locus, and attendant functional consequences, is poorly defined. Moreover, other important ethnic groups in the US, notably Hispanics, have been quite neglected in this research area, despite evidence for population-specific polymorphisms in the CYP2C9 gene. Therefore, we will; Specific Aim 1: Identify the spectrum of distal regulatory polymorphisms that exist at the CYP2C9 locus. SNP discovery will be performed in a panel of 90 DNA samples from the Polymorphism Discovery Resource. SNP validation and allele frequency determinations will then be carried out in White and Hispanic populations. Specific Aim 2: Determine the functional significance of new promoter and coding-region polymorphisms in CYP2C9. Mechanisms underlying changes in function will be probed with reporter constructs, deletion analysis, DNA/binding protein assays, recombinantly expressed proteins and stably-transfected cell lines. Specific Aim 3: Determine the impact of new CYP2C9 polymorphisms on anticoagulation-related outcomes in previously phenotyped Caucasian patients by resequencing across 60 kbp of the CYP2C9 gene from 185 pre-existing warfarin patient DNA samples. Aims 1 and 2 will test the hypothesis that; novel, functionally important polymorphisms remain to be elucidated within the CYP2C9 locus, some of which will be population-selective. Aim 3 will test the hypothesis that; promoter-region SNPs in the CYP2C9 gene are a determinant of warfarin dose. Successful completion of these studies will impact the ability of clinicians to predict the likelihood of adverse drug reactions to warfarin, and other drugs that are CYP2C9 substrates, arising in minority populations.
描述(由申请人提供):本研究的长期目标是确定不同种族受试者中人类CYP2C9基因遗传变异的临床后果,并了解CYP2C9酶功能活性遗传基础改变的分子机制。CYP2C9是P450的主要人类肝脏形式,代谢约15%的I期清除药物。已经证实,使用低治疗指数药物如华法林治疗具有常见CYP2C9*2和CYP2C9*3变异体的患者具有重要的临床意义。这些都是药物不良反应(adr),由于过度用药,可能导致重大的,但潜在的可避免的,患者的健康成本。尽管存在大量关于高加索人CYP2C9多态性的信息,但CYP2C9位点的全谱遗传变异以及随之而来的功能后果,尚不清楚。此外,尽管有证据表明CYP2C9基因存在群体特异性多态性,但美国其他重要的种族群体,特别是西班牙裔,在这一研究领域一直被忽视。因此,我们将;

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(6)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Allan Edward Rettie其他文献

Allan Edward Rettie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Allan Edward Rettie', 18)}}的其他基金

New Vistas in Vitamin K Metabolism
维生素 K 代谢的新前景
  • 批准号:
    8477918
  • 财政年份:
    2013
  • 资助金额:
    $ 34.72万
  • 项目类别:
New Vistas in Vitamin K Metabolism
维生素 K 代谢的新前景
  • 批准号:
    9031119
  • 财政年份:
    2013
  • 资助金额:
    $ 34.72万
  • 项目类别:
Genotype-Dependent Drug Interactions
基因型依赖性药物相互作用
  • 批准号:
    8380462
  • 财政年份:
    2012
  • 资助金额:
    $ 34.72万
  • 项目类别:
Genotype-Dependent Drug Interactions
基因型依赖性药物相互作用
  • 批准号:
    8334083
  • 财政年份:
    2011
  • 资助金额:
    $ 34.72万
  • 项目类别:
Genotype-Dependent Drug Interactions
基因型依赖性药物相互作用
  • 批准号:
    8118439
  • 财政年份:
    2010
  • 资助金额:
    $ 34.72万
  • 项目类别:
Drug Interactions
药物相互作用
  • 批准号:
    7559327
  • 财政年份:
    2008
  • 资助金额:
    $ 34.72万
  • 项目类别:
Genotype-Dependent Drug Interactions
基因型依赖性药物相互作用
  • 批准号:
    7559316
  • 财政年份:
    2008
  • 资助金额:
    $ 34.72万
  • 项目类别:
Pharmacogenetics of ADRs: Warfarin Toxicity
ADR 的药物遗传学:华法林毒性
  • 批准号:
    7668284
  • 财政年份:
    2004
  • 资助金额:
    $ 34.72万
  • 项目类别:
Pharmacogenetics of ADRs: Warfarin Toxicity
ADR 的药物遗传学:华法林毒性
  • 批准号:
    7021349
  • 财政年份:
    2004
  • 资助金额:
    $ 34.72万
  • 项目类别:
Pharmacogenetics of ADRs: Warfarin Toxicity
ADR 的药物遗传学:华法林毒性
  • 批准号:
    7216381
  • 财政年份:
    2004
  • 资助金额:
    $ 34.72万
  • 项目类别:

相似海外基金

Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10722686
  • 财政年份:
    2023
  • 资助金额:
    $ 34.72万
  • 项目类别:
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation
病原体诱导的血液凝固中脂质过氧化和焦亡诱导的组织因子激活
  • 批准号:
    10571353
  • 财政年份:
    2023
  • 资助金额:
    $ 34.72万
  • 项目类别:
Elucidation of changes in electrical properties during the blood coagulation process and its use for measurement of blood coagulation status during extracorporeal circulation
阐明血液凝固过程中电特性的变化及其在体外循环期间血液凝固状态测量中的应用
  • 批准号:
    23K08266
  • 财政年份:
    2023
  • 资助金额:
    $ 34.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis
SBIR II 期:低容量凝血分析的创新平台
  • 批准号:
    2134020
  • 财政年份:
    2022
  • 资助金额:
    $ 34.72万
  • 项目类别:
    Cooperative Agreement
Construction of a multilayered network to represent blood coagulation process
构建代表血液凝固过程的多层网络
  • 批准号:
    22K12252
  • 财政年份:
    2022
  • 资助金额:
    $ 34.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Protein S Regulates Blood Coagulation by Inhibiting Factor IXa
Protein S 通过抑制 IXa 因子调节凝血
  • 批准号:
    10616732
  • 财政年份:
    2022
  • 资助金额:
    $ 34.72万
  • 项目类别:
Development of thrombus prevention technology for ECMO devices based on the blood coagulation mechanism caused by viral infections
基于病毒感染凝血机制的ECMO装置血栓预防技术开发
  • 批准号:
    21K08817
  • 财政年份:
    2021
  • 资助金额:
    $ 34.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10452687
  • 财政年份:
    2021
  • 资助金额:
    $ 34.72万
  • 项目类别:
SBIR Phase II: CoagCare-A POC Blood Coagulation Diagnostic Platform That Utilizes A Hand-held Meter and Mechanically Sensitive Test Strips for Broad Spectrum Hemostasis Monitoring
SBIR II 期:CoagCare - POC 凝血诊断平台,利用手持式仪表和机械敏感试纸条进行广谱止血监测
  • 批准号:
    2050272
  • 财政年份:
    2021
  • 资助金额:
    $ 34.72万
  • 项目类别:
    Cooperative Agreement
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10283268
  • 财政年份:
    2021
  • 资助金额:
    $ 34.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了